Sickle Cell Disease - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 190
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S4DED964F45EN
Leaflet:

Download PDF Leaflet

Sickle Cell Disease - Pipeline Review, H2 2017
Sickle Cell Disease - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H2 2017, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 4, 11, 25, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Sickle Cell Disease - Overview
Sickle Cell Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sickle Cell Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sickle Cell Disease - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
Addmedica SAS
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
ArQule Inc
Bio Products Laboratory Ltd
Bioverativ Inc
bluebird bio Inc
Bristol-Myers Squibb Co
Calimmune Inc
CRISPR Therapeutics
CSL Ltd
Daiichi Sankyo Co Ltd
Editas Medicine Inc
Errant Gene Therapeutics LLC
Gamida Cell Ltd
Genethon SA
Gilead Sciences Inc
Global Blood Therapeutics Inc
Incyte Corp
Ironwood Pharmaceuticals Inc
La Jolla Pharmaceutical Company
MaxCyte Inc
Merck & Co Inc
Morphogenesis Inc
NKT Therapeutics Inc
Novartis AG
Orphagen Pharmaceuticals Inc
Prolong Pharmaceuticals LLC
Protagonist Therapeutics Inc
ReveraGen BioPharma Inc
Sancilio & Company Inc
Sangamo Therapeutics Inc
Sickle Cell Disease - Drug Profiles
(decitabine + tetrahydrouridine) - Drug Profile
AB-110 - Drug Profile
ACY-957 - Drug Profile
ambrisentan - Drug Profile
AP-01 - Drug Profile
apixaban - Drug Profile
ARQ-092 - Drug Profile
BB-305 - Drug Profile
benserazide - Drug Profile
BIVV-003 - Drug Profile
CAL-H - Drug Profile
CordIn - Drug Profile
crizanlizumab - Drug Profile
CTX-001 - Drug Profile
didox - Drug Profile
Drugs to Inhibit PRMT5 for Sickle Cell Anemia - Drug Profile
DRX-194 - Drug Profile
GBT-440 - Drug Profile
Gene Therapy for Sickle Cell Anemia - Drug Profile
Gene Therapy for Sickle Cell Disease - Drug Profile
Gene Therapy for Sickle Cell Disease - Drug Profile
Gene Therapy for Sickle Cell Disease and Thalassemia - Drug Profile
Gene Therapy to Activate Gamma Globin for Sickle Cell Disease - Drug Profile
Gene Therapy to Activate IGF2BP1 for Sickle Cell Disease and Thalassemia - Drug Profile
haptoglobin (human) - Drug Profile
haptoglobin + hemopexin - Drug Profile
HBI-002 - Drug Profile
HBI-137 - Drug Profile
hydroxyurea - Drug Profile
hydroxyurea - Drug Profile
IMR-687 - Drug Profile
INCB-59872 - Drug Profile
IW-1701 - Drug Profile
LJPC-401 - Drug Profile
luspatercept - Drug Profile
M-012 - Drug Profile
NiCord - Drug Profile
NKTT-120 - Drug Profile
panobinostat - Drug Profile
pentosan polysulfate sodium - Drug Profile
Polysaccharide to Inhibit Coagulation Factor X for Deep Vein Thrombosis and Sickle Cell Disease - Drug Profile
prasugrel hydrochloride - Drug Profile
Protein for Sickle Cell Disease - Drug Profile
PTG-300 - Drug Profile
RCY-1497 - Drug Profile
RN-1 - Drug Profile
RNAi Gene Therapy for Sickle Cell Disease and Beta Thalassemia - Drug Profile
Sanguinate - Drug Profile
SC-411 - Drug Profile
SCD-101 - Drug Profile
SCPF - Drug Profile
Small Molecules for Sickle Cell Disease - Drug Profile
Small Molecules for Sickle Cell Disease - Drug Profile
Small Molecules to Inhibit HDAC for Oncology and Sickle Cell Disease - Drug Profile
Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours - Drug Profile
sotatercept - Drug Profile
Stem Cell Therapy for Beta Thalassemia and Sickle Cell Disease - Drug Profile
Stem Cell Therapy to Activate Beta Globin for Sickle Cell Disease - Drug Profile
Trichosic - Drug Profile
vamorolone - Drug Profile
Sickle Cell Disease - Dormant Projects
Sickle Cell Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Sickle Cell Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Sickle Cell Disease - Pipeline by Acceleron Pharma Inc, H2 2017
Sickle Cell Disease - Pipeline by Addmedica SAS, H2 2017
Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H2 2017
Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H2 2017
Sickle Cell Disease - Pipeline by ArQule Inc, H2 2017
Sickle Cell Disease - Pipeline by Bio Products Laboratory Ltd, H2 2017
Sickle Cell Disease - Pipeline by Bioverativ Inc, H2 2017
Sickle Cell Disease - Pipeline by bluebird bio Inc, H2 2017
Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H2 2017
Sickle Cell Disease - Pipeline by Calimmune Inc, H2 2017
Sickle Cell Disease - Pipeline by CRISPR Therapeutics, H2 2017
Sickle Cell Disease - Pipeline by CSL Ltd, H2 2017
Sickle Cell Disease - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Sickle Cell Disease - Pipeline by Editas Medicine Inc, H2 2017
Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H2 2017
Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H2 2017
Sickle Cell Disease - Pipeline by Genethon SA, H2 2017
Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H2 2017
Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H2 2017
Sickle Cell Disease - Pipeline by Incyte Corp, H2 2017
Sickle Cell Disease - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
Sickle Cell Disease - Pipeline by La Jolla Pharmaceutical Company, H2 2017
Sickle Cell Disease - Pipeline by MaxCyte Inc, H2 2017
Sickle Cell Disease - Pipeline by Merck & Co Inc, H2 2017
Sickle Cell Disease - Pipeline by Morphogenesis Inc, H2 2017
Sickle Cell Disease - Pipeline by NKT Therapeutics Inc, H2 2017
Sickle Cell Disease - Pipeline by Novartis AG, H2 2017
Sickle Cell Disease - Pipeline by Orphagen Pharmaceuticals Inc, H2 2017
Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals LLC, H2 2017
Sickle Cell Disease - Pipeline by Protagonist Therapeutics Inc, H2 2017
Sickle Cell Disease - Pipeline by ReveraGen BioPharma Inc, H2 2017
Sickle Cell Disease - Pipeline by Sancilio & Company Inc, H2 2017
Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H2 2017
Sickle Cell Disease - Dormant Projects, H2 2017
Sickle Cell Disease - Dormant Projects, H2 2017 (Contd.1), H2 2017

LIST OF FIGURES

Number of Products under Development for Sickle Cell Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Acceleron Pharma Inc
Addmedica SAS
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
ArQule Inc
Bio Products Laboratory Ltd
Bioverativ Inc
bluebird bio Inc
Bristol-Myers Squibb Co
Calimmune Inc
CRISPR Therapeutics
CSL Ltd
Daiichi Sankyo Co Ltd
Editas Medicine Inc
Errant Gene Therapeutics LLC
Gamida Cell Ltd
Genethon SA
Gilead Sciences Inc
Global Blood Therapeutics Inc
Incyte Corp
Ironwood Pharmaceuticals Inc
La Jolla Pharmaceutical Company
MaxCyte Inc
Merck & Co Inc
Morphogenesis Inc
NKT Therapeutics Inc
Novartis AG
Orphagen Pharmaceuticals Inc
Prolong Pharmaceuticals LLC
Protagonist Therapeutics Inc
ReveraGen BioPharma Inc
Sancilio & Company Inc
Sangamo Therapeutics Inc
Skip to top


Ask Your Question

Sickle Cell Disease - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: